{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"59.9","upperLimit":"83.1","value":"72.3"},{"groupId":"OG001","lowerLimit":"66.9","upperLimit":"88.8","value":"78.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"40"}],"units":"Participants"}],"description":"Death from any cause. The time to this event is the time from HCT to death, loss to follow-up, or end of study (whichever comes first).\n\nThe overall survival probability and 90% CI will be calculated by the Kaplan Meier product limit estimator.","dispersionType":"90% Confidence Interval","groups":[{"description":"Participants received one of three regimens: cyclophosphamide and total body irradiation; busulfan and cyclophosphamide; or fludarabine and busulfan","id":"OG000","title":"Myeloablative Conditioning (MAC)"},{"description":"Participants received one of two regimens: fludarabine, cyclophosphamide, and low-dose total body irradiation","id":"OG001","title":"Reduced Intensity Conditioning (RIC)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"365 days post transplant","title":"Overall Survival","type":"PRIMARY","unitOfMeasure":"percentage of participants"}